vaccin
effect
mean
prevent
individu
infect
pathogen
virus
howev
virus
hepat
c
viru
evad
immun
system
thu
imped
effect
vaccin
virus
therefor
antivir
small
molecul
inhibitor
inhibit
critic
step
viru
lifecycl
infect
individu
critic
need
battl
viru
infect
inhibitor
could
curb
viru
number
bodi
interf
viral
entri
host
cell
function
assembl
viral
replic
machineri
releas
virus
infect
cell
ideal
antivir
agent
complet
erad
virus
bodi
without
affect
normal
cellular
metabol
howev
featur
yet
achiev
two
main
problem
associ
use
drug
emerg
resist
viral
strain
cytotox
host
cell
virus
replic
genom
high
error
rate
mutat
viral
gene
code
surfac
antigen
enzym
replic
compon
often
confer
drug
resist
capabl
virus
also
cytotox
often
aris
antivir
drug
usual
design
target
inhibit
certain
function
motif
viral
protein
motif
share
high
degre
amino
acid
sequenc
similar
across
differ
speci
associ
conserv
function
one
exampl
demonstr
motif
similar
viral
human
protein
helicas
deadbox
domain
larg
conserv
hcv
helicas
human
rna
helicas
although
offtarget
cross
reactiv
often
lead
mild
side
effect
sometim
seriou
major
effect
health
exampl
revers
transcriptas
inhibitor
zidovudin
nucleosid
analogu
compet
natur
deoxynucleotid
dntp
incorpor
grow
dna
chain
viral
revers
transcriptas
treatment
zidovudin
delay
progress
aid
clear
viru
drug
resist
mutant
usual
aris
moreov
longterm
highdos
treatment
zidovudin
caus
seriou
complic
anemia
neutropenia
hepatotox
cardiomyopathi
myopathi
aptam
vitro
evolv
nucleic
acid
capabl
perform
specif
function
process
identifi
function
ligand
vast
popul
random
sequenc
call
systemat
evolut
ligand
exponenti
enrich
selex
typic
initi
combinatori
librari
contain
central
random
region
nucleotid
flank
fix
sequenc
end
fix
sequenc
use
pcr
amplif
selex
round
random
sequenc
least
entiti
repres
extraordinari
molecular
divers
structur
complex
screen
high
affin
bioactiv
aptam
target
date
dozen
selex
methodolog
develop
isol
aptam
purifi
protein
even
whole
cell
whole
virus
use
purifi
protein
select
target
advantag
easi
control
achiev
optim
sequenc
enrich
selex
whole
cell
viru
select
prefer
biomark
unknown
moreov
sinc
target
protein
may
present
modifi
form
exist
protein
complex
may
mask
therefor
inaccess
aptam
reflect
physiolog
condit
protein
display
cell
surfac
rather
isol
purifi
protein
gener
selex
compris
cycl
four
sequenti
step
bind
target
partit
targetbound
aptam
recoveri
targetbound
aptam
amplif
recov
sequenc
select
cycl
complet
function
aptam
sequenc
enrich
among
random
sequenc
librari
sinc
incept
selex
technolog
two
decad
ago
extraordinari
divers
molecul
screen
manner
led
discoveri
aptam
bind
exquisit
specif
extraordinari
strength
macugen
pfizer
use
treat
agerel
macular
degener
first
aptam
therapeut
approv
unit
state
food
drug
administr
fda
proven
mileston
aptam
histori
mani
novel
aptam
current
evalu
clinic
trial
treat
lifethreaten
diseas
acut
myeloid
leukemia
renal
cell
carcinoma
acut
coronari
syndrom
choroid
neovascular
addit
aptam
easili
conjug
chemic
manufactur
use
aptam
chimera
target
deliveri
enhanc
potenc
secondari
agent
progress
rapidli
review
focu
recent
progress
prospect
use
aptam
varieti
human
viral
pathogen
repres
exampl
aptam
chimera
highlight
final
discuss
challeng
advanc
antivir
aptam
therapeut
prospect
futur
success
rt
key
multifunct
enzym
retrovir
life
cycl
dna
polymeras
activ
rna
dna
templat
ribonucleas
h
activ
rnadna
hybrid
templat
rt
catalyz
convers
singl
strand
genom
viral
rna
doubl
strand
provir
dna
turn
integr
host
genom
current
rt
one
main
drug
target
hivaid
mani
nucleosid
inhibitor
eg
azt
ddi
ddc
nonnucleosid
inhibitor
eg
snevirapin
delavirdin
efavirenz
current
use
patient
tuerk
gold
identifi
rna
aptam
rt
rna
pool
span
random
region
use
vitro
selex
select
antirt
aptam
contain
consensu
sequenc
result
format
rna
pseudoknot
rna
pseudoknot
report
bind
rt
picomolar
rang
inhibitori
effect
replic
sinc
discoveri
numer
rna
dna
aptam
variou
length
rais
rt
use
inhibit
viru
replic
explor
exampl
singl
strand
dna
aptam
high
affin
rnase
h
domain
rt
isol
use
recombin
rt
select
dna
ligand
could
greatli
diminish
infect
human
cell
similarli
doublestrand
dna
thioaptam
contain
thiophosph
backbon
select
rnase
h
domain
rt
use
vitro
combinatori
select
method
one
lead
thioaptam
could
specif
bind
rt
dissoci
constant
kd
nm
significantli
inhibit
infect
dosedepend
manner
addit
aptam
wildtyp
wt
rt
sever
rna
aptam
target
drugresist
rt
mutant
isol
one
aptam
bound
signific
affin
wt
rt
would
like
allow
specif
detect
rt
variant
antirt
aptam
intracellularli
express
togeth
flank
selfcleav
ribozym
gener
aptam
rna
transcript
minim
flank
sequenc
express
aptam
infect
cell
led
encapsid
aptam
virion
particl
subsequ
block
replic
aptam
also
effect
suppress
drugresist
variant
hiv
subtyp
eg
subtyp
b
e
f
recent
lang
et
al
optim
express
cassett
extend
tertiarystabil
hammerhead
ribozym
replac
enhanc
selfcleavag
activ
stabl
clonal
cell
line
express
aptam
optim
construct
strongli
suppress
infecti
viru
use
high
multipl
infect
moi
integras
retroviru
encod
enzym
catalyz
insert
provir
dna
hostcel
genom
essenti
retroviru
replic
promis
target
develop
antiretrovir
drug
soultrait
et
al
isol
sever
dna
aptam
could
strongli
inhibit
rnase
h
activ
associ
rt
xray
structur
analysi
indic
strong
similar
rnase
h
domain
rt
catalyt
core
author
investig
truncat
version
dna
aptam
rt
rnase
h
could
also
bind
found
case
dna
antirt
aptam
effici
block
process
strand
transfer
activ
use
nanomolar
concentr
vitro
abolish
replic
infect
human
cell
structur
studi
reveal
dna
aptam
contain
grich
sequenc
could
form
stabl
noncanon
gquadruplex
structur
dockingbas
model
complex
suggest
dna
aptam
locat
within
channel
tetramer
integras
mutual
fit
could
block
sever
catalyt
amino
acid
residu
essenti
integras
function
bind
site
aptam
may
contribut
activ
addit
variou
gquadruplex
aptam
eg
proven
effect
inhibit
vitro
therefor
regard
potenti
antihiv
therapeut
agent
gag
polyprotein
major
structur
protein
synthes
cytoplasm
infect
cell
orchestr
assembl
releas
particl
necessari
suffici
format
noninfecti
viruslik
particl
involv
assembl
virion
matur
particl
releas
well
earli
postentri
step
viru
replic
virion
matur
gag
cleav
sever
compon
protein
matrix
protein
capsid
protein
ca
nucleocapsid
protein
nc
late
domain
two
small
spacer
peptid
protein
play
specif
role
life
cycl
mutat
domain
gag
lead
defect
particl
assembl
loss
infect
abil
rna
aptam
specif
gag
polyprotein
inhibit
replic
explor
ramalingam
et
al
select
rna
aptam
gag
protein
lack
ntermin
myrist
ctermin
gag
select
aptam
show
strong
bind
affin
nc
entir
gag
protein
bind
studi
reveal
ncbinder
could
specif
compet
packag
signal
bind
moreov
ncbind
aptam
disrupt
gaggenom
rna
interact
neg
affect
genom
rna
transcript
process
stabil
nc
protein
play
import
role
encapsid
viral
rna
assembl
viral
particl
nc
protein
specif
recogn
viral
genom
rna
specif
bind
viral
psi
sequenc
thu
select
encapsid
viral
rna
among
differ
cellular
rna
pool
nc
highli
conserv
therefor
excel
target
antivir
therapi
kim
et
al
describ
select
stabil
rna
aptam
nc
surfac
plasmon
reson
spr
analysi
gel
shift
assay
show
select
rna
aptam
specif
bound
target
nc
protein
high
affin
compet
psi
rna
bind
nc
protein
furthermor
linear
aptam
tailor
form
circular
rna
show
higher
stabil
bind
affin
nc
protein
thu
provid
valuabl
inhibitor
viral
packag
similar
studi
antinc
rna
aptam
shown
complet
abolish
nc
bind
stabl
transactiv
respons
hairpin
psi
rna
stemloop
rna
aptam
express
cell
suppress
packag
viral
genom
rna
envelop
glycoprotein
hiv
consist
exterior
glycoprotein
transmembran
domain
play
import
role
viral
entri
cell
infect
initi
interact
human
cell
surfac
receptor
subsequ
lead
fusion
viral
membran
target
cell
membran
interact
suggest
anoth
potenti
therapeut
target
block
infect
rna
aptam
bind
protein
shown
neutral
exampl
use
spr
jame
colleagu
develop
sever
antihiv
rna
aptam
block
interact
moreov
mutat
analysi
function
studi
aptam
demonstr
specif
interact
conserv
coreceptor
region
stain
deriv
neutral
infect
human
peripher
blood
mononuclear
cell
select
aptam
suppress
infect
clinic
isol
deriv
group
subtyp
c
e
f
group
addit
research
conduct
detail
character
one
neutral
aptam
found
minim
region
aptam
essenti
bind
compris
threeway
junction
link
two
helixloop
close
helix
accordingli
truncat
version
aptam
design
effici
prevent
interact
host
cell
recent
sever
shorten
synthet
deriv
aptam
design
assess
antivir
activ
one
aptam
tightli
bound
consensu
subtyp
c
neutral
isol
subtyp
inhibitori
concentr
nanomolar
rang
without
caus
toxic
test
primari
cell
furthermor
combin
fusion
inhibitor
bind
site
monoclon
antibodi
synergist
effect
observ
suggest
may
potenti
adjuv
antihiv
agent
recent
use
nitrocellulos
membran
base
vitro
selex
procedur
rna
librari
group
also
succeed
select
sever
substitut
rna
aptam
bind
protein
nanomolar
affin
evolv
aptam
effici
inhibit
replic
iiib
bal
jrfl
well
sever
clinic
isol
specif
intern
cell
express
take
advantag
bind
properti
aptam
test
concept
use
aptam
deliv
small
interf
si
rna
infect
cell
goal
enhanc
therapeut
efficaci
reduc
offtarget
effect
sirna
sirna
exploit
new
class
medicin
varieti
diseas
inhibit
express
complementari
rna
transcript
clinic
translat
dampen
specif
cell
deliveri
intern
chimera
approach
made
two
design
aptamerdic
substrat
sirna
dsirna
conjug
cell
typespecif
sirna
deliveri
coval
aptamersirna
chimera
noncoval
aptamersticksirna
chimera
figur
coval
aptamersirna
chimera
figur
first
identifi
aptam
provid
neutral
activ
even
sirna
conjug
serv
vehicl
select
deliv
sirna
infect
cell
activ
aptamersirna
chimera
evalu
human
raghu
mous
model
infect
chimera
significantli
reduc
plasma
viral
load
maintain
level
equival
uninfect
control
mice
case
aptamersticksirna
chimera
figur
singl
aptam
use
combin
three
differ
sirna
target
tatrev
transcript
host
depend
factor
result
knockdown
target
mrna
potent
inhibit
replic
well
protect
viralinduc
tcell
deplet
vivo
advantag
stick
design
facilit
effect
interchang
differ
sirna
singl
aptam
requir
avert
viral
resist
sirna
compon
followup
treatment
aptamercocktail
dsirna
conjug
viral
rebound
result
complet
longterm
suppress
viral
load
suggest
facil
target
approach
combinatori
deliveri
antivir
host
sirna
therapi
vivo
viral
transactiv
tat
protein
consist
amino
acid
bind
specif
regulatori
element
tran
activ
respons
tar
element
longtermin
repeat
ltr
regul
viral
transcript
tat
also
influenc
growth
metabol
host
cell
import
effici
revers
transcript
rna
aptam
rnatat
bound
effici
tat
protein
isol
vitro
select
procedur
compar
authent
tar
rna
dissoci
constant
rnatat
tat
higher
rnatat
aptam
show
high
affin
tat
interact
cellular
protein
like
effici
suitabl
decoy
cellular
tar
rna
interact
sever
cellular
factor
within
cell
inhibit
transcript
variou
gene
result
demonstr
rnatat
aptam
could
specif
prevent
tatdepend
transactiv
vitro
vivo
rev
viral
encod
sequencespecif
rnabind
protein
play
critic
role
nuclear
export
introncontain
rna
rev
shuttl
nucleu
cytoplasm
harbor
nuclear
local
signal
nuclear
export
signal
rev
directli
bind
unsplic
incomplet
splice
viral
rna
cisact
rev
respons
element
sequenc
rna
aptam
rais
rev
protein
vitro
evolut
structur
analysi
chemic
modif
aptam
reveal
two
major
region
rna
aptam
respons
interact
rev
protein
region
might
provid
start
point
develop
therapeut
nucleic
acid
therapi
furthermor
revbind
aptam
antienv
ribozym
construct
rsv
cmv
promot
high
transcript
rate
produc
stabl
transcript
local
transcript
within
cytoplasm
compart
expect
result
cassett
could
effect
suppress
product
hiv
provir
clone
tar
element
stem
loop
present
end
rna
mediat
transactiv
transcript
bind
viral
protein
tat
interact
tar
rna
tat
protein
increas
process
rna
polymeras
allow
high
yield
synthesi
fulllength
retrovir
genom
therefor
bind
oligonucleotid
ligand
aptam
could
abl
compet
interact
tar
rna
tat
could
prevent
transcript
boiziau
et
al
perform
vitro
select
identifi
ligand
specif
tar
round
selectionamplif
sever
dna
aptam
isol
structur
analysi
reveal
select
dna
aptam
could
fold
imperfect
stemloop
structur
present
consensu
motif
six
central
base
consensu
complementari
tar
apic
region
allow
format
rnadna
kiss
complex
presenc
mm
magnesium
complex
interfer
tar
function
observ
magnesium
concentr
lower
physiolog
concentr
mm
suppos
aptam
lower
bind
affin
could
effici
compet
viral
cellular
protein
induc
transcript
therefor
research
ad
counterselect
step
elimin
binder
lower
affin
one
aptam
could
shorten
dna
dissoci
constant
nm
inhibitori
capabl
significantli
alter
similarli
rna
aptam
tar
also
develop
select
sequenc
fold
imperfect
hairpin
display
consensu
motif
complementari
entir
tar
loop
lead
format
tar
rnaaptam
kiss
complex
lower
nanomolar
dissoci
constant
kd
nm
mm
magnesium
select
rna
aptam
attribut
close
aptam
loop
consensu
g
residu
moreov
antitar
rna
aptam
isol
genom
human
librari
theoret
genom
selex
librari
contain
cellular
rna
transcript
identifi
put
function
interact
involv
rna
motif
genom
selex
use
studi
rnarna
interact
search
rna
might
express
low
level
case
tar
aptam
one
select
aptam
form
complex
tar
kiss
interact
lower
dissoci
constant
previous
identifi
aptam
kd
nm
vs
nm
virusresist
transgen
cell
macrophag
express
tar
aptam
either
alon
combin
other
nucleic
acid
therapeut
produc
lentivir
gene
transduct
progenitor
cell
differenti
lymphocyt
macrophag
challeng
mark
resist
infect
seen
exampl
tripl
combin
lentivir
construct
compos
tar
rna
decoy
tatrev
shrna
transcleav
hammerhead
ribozym
effici
transduc
human
progenitor
cell
transduc
cell
increas
suppress
day
compar
cell
receiv
singl
antitatrev
shrna
doubl
combin
shrnaribozym
decoy
recent
tripl
construct
use
ex
vivo
gene
deliveri
hematopoiet
stem
cell
human
clinic
trial
lentivir
transduc
cell
success
engraft
four
infus
patient
day
unexpect
infusionrel
toxic
seen
longterm
month
express
ectop
express
shrna
ribozym
multipl
peripher
blood
cell
lineag
two
transplant
patient
observ
protein
hcv
multifunct
enzym
two
distinct
domain
amino
n
termin
trypsinlik
serin
proteas
activ
compris
onethird
protein
carboxyl
c
termin
ntpdepend
rnadna
helicas
unwind
activ
remain
two
third
gener
proteas
activ
cleav
junction
nonstructur
protein
helicas
activ
unwind
doublestrand
rna
gener
rnadepend
rna
polymeras
genom
replic
essenti
hcv
life
cycl
mani
aptam
evolv
potenti
antihcv
agent
kumar
et
al
isol
rna
aptam
random
pool
compris
base
select
aptam
bound
specif
proteas
domain
inhibit
activ
vitro
evalu
enzym
kinet
reveal
aptam
inhibit
proteas
activ
mix
competit
noncompetit
fashion
respect
substrat
interestingli
aptam
moder
inhibit
helicas
activ
even
though
aptam
bound
proteas
domain
although
aptam
potenti
serv
dualfunct
inhibitor
inhibitori
concentr
high
ki
appear
significantli
higher
aptam
target
protein
aptam
low
efficaci
new
set
aptam
protein
reevolv
use
slightli
modifi
select
strategi
truncat
proteas
domain
use
select
target
instead
entir
protein
random
core
region
use
selex
instead
random
core
region
consequ
three
class
conserv
aptam
identifi
round
select
dissoci
constant
aptam
nm
could
inhibit
proteas
activ
truncat
entir
noncompetit
manner
mutat
analysi
aptam
reveal
sequenc
requir
proteas
inhibit
stem
stem
iii
loop
iii
aptam
use
aptam
vivo
requir
may
express
intracellularli
therefor
vivo
aptam
express
system
design
combin
aptam
cisact
genom
human
hepat
delta
viru
hdv
ribozym
construct
chimer
aptam
insert
nonfunct
stem
iv
region
hdv
ribozym
aptam
would
protect
exonucleas
degrad
presenc
tightli
pack
structur
hdv
ribozym
henc
remain
stabl
function
cell
furthermor
chimera
attach
nuclear
export
signal
array
tandem
repeat
express
plasmid
order
increas
cytoplasm
level
cell
evalu
express
system
cultur
cell
show
effici
proteas
inhibit
activ
similar
aptam
alon
hcv
helicas
report
preferenti
bind
poli
u
sequenc
therefor
fukuda
et
al
ad
poli
u
tail
end
aptam
addit
poli
u
tail
increas
bind
proteas
inhibit
also
result
addit
abil
inhibit
helicas
compar
origin
aptam
modifi
u
aptam
potent
proteas
activ
effici
inhibit
unwind
dna
helicas
poli
u
tail
similar
decoy
mask
substrat
bind
site
helicas
unfortun
poli
u
tail
moder
inhibit
helicas
therefor
anoth
selex
hcv
helicas
domain
perform
identifi
specif
hcv
helicas
aptam
improv
round
select
aptam
strongli
inhibit
helicas
activ
vitro
nm
although
hcv
helicas
use
ntp
energi
sourc
unwind
nucleic
acid
helicas
activ
protein
inhibit
aptam
ntpase
activ
affect
suggest
aptam
may
bind
nucleic
acid
bind
site
helicas
block
unwind
activ
furthermor
given
identif
specif
effect
aptam
proteas
helicas
domain
hcv
dualfunct
nanoparticl
creat
conjug
proteas
aptam
helicas
aptam
poli
u
spacer
distanc
two
aptam
care
adjust
result
chimera
effect
inhibit
proteasehelicas
activ
vitro
particular
helicas
activ
fourfold
greater
inhibit
compar
aptam
alon
cell
cultur
experi
demonstr
chimera
effect
inhibit
proteas
activ
live
cell
hcv
genom
replic
system
viral
polymeras
hcv
rnadepend
rna
polymeras
essenti
transcrib
full
length
hcv
genom
synthesi
viral
rna
synthes
neg
strand
rna
serv
templat
synthesi
new
posit
rna
strand
essenti
role
hcv
life
cycl
made
attract
develop
antihcv
agent
biroccio
et
al
isol
rna
aptam
truncat
protein
lack
ctermin
membran
local
signal
delet
ctermin
sequenc
help
enhanc
stabil
catalyt
activ
protein
improv
selex
procedur
select
aptam
share
consensu
sequenc
fold
stemloop
structur
particular
one
aptam
bound
protein
high
affin
noncompetit
inhibit
activ
polymeras
respect
templat
rna
observ
suggest
aptam
templat
rna
bind
region
protein
similarli
bellecav
et
al
identifi
two
dna
aptam
specif
bound
inhibit
polymeras
activ
howev
aptam
use
two
differ
mechan
inhibit
enzym
aptam
compet
templat
rna
inhibit
step
rna
synthesi
ie
initi
elong
aptam
compet
poorli
rna
templat
inhibit
initi
cell
cultur
studi
reveal
aptam
could
inhibit
viral
rna
synthesi
interf
viral
particl
product
hcv
infect
cell
hcv
aptam
includ
f
modifi
aptam
evolv
lee
et
al
transfect
aptam
cell
significantli
suppress
replic
hcv
genotyp
gener
escap
mutant
virus
caus
cellular
toxic
potent
aptam
modifi
conjug
cholesterol
galactosepolyethylen
glycol
ligand
increas
stabil
specif
liver
intern
ribosom
entri
site
ire
highli
conserv
complex
rna
structur
locat
nontransl
region
hcv
genom
hcv
ire
associ
host
cell
small
ribosom
unit
eukaryot
initi
factor
mediat
translat
initi
hcv
genom
cap
independ
manner
ire
rna
four
conserv
domain
iiv
structurefunct
relationship
wellunderstood
figur
identifi
rna
aptam
domain
ii
ire
kikuchi
et
al
use
biotinyl
dna
probe
complementari
extens
domain
ii
fix
ire
streptavidin
magnet
bead
round
select
almost
clone
contain
conserv
sequenc
complementari
apic
loop
domain
ii
observ
suggest
apic
loop
domain
ii
may
expos
interact
cellular
molecul
access
contact
aptam
one
aptam
low
dissoci
constant
ire
domain
ii
kd
nm
aptam
moder
inhibit
iresdepend
translat
similarli
research
group
isol
rna
aptam
capabl
bind
domain
iiiiv
aptam
also
share
conserv
sequenc
complementari
apic
loop
domain
iiid
loop
known
critic
region
iresdepend
translat
notabl
aptam
show
high
affin
domain
iii
strongli
inhibit
iresdepend
translat
fireflyluciferas
mrna
mammalian
cell
furthermor
conjug
domain
iispecif
aptam
domain
iiispecif
aptam
bound
ire
effici
two
parent
aptam
also
inhibit
iresdepend
translat
time
effici
aptam
romerolopez
et
al
develop
innov
aptamerribozym
chimera
compris
aptam
target
domain
iv
ire
hammerhead
ribozym
target
hcv
genom
identifi
chimera
contain
cleav
bind
activ
rna
librari
pool
first
design
basi
wellcharacter
hammerhead
ribozym
cleav
posit
hcv
genom
long
random
region
attach
end
ribozym
identif
potent
chimera
involv
two
step
select
aptam
specif
bound
ire
identif
highaffin
aptam
retain
catalyt
activ
cleav
hcv
rna
consequ
chimer
molecul
compos
two
inhibitor
identifi
activ
function
chimer
inhibitor
vitro
suggest
conjug
aptam
ribozym
domain
caus
loss
function
aptam
domain
bound
domain
iv
ire
interf
format
product
ribosom
complex
ribozym
domain
reduc
hcv
rna
level
subgenom
replicon
system
cleav
viral
genom
studi
confirm
success
combin
differ
function
nucleic
acid
produc
dualfunct
inhibitor
hbv
surfac
antigen
hbsag
situat
membran
hbv
hbv
replic
hbsag
overexpress
surfac
hbsag
hepatocyt
hbsag
often
use
target
hbv
diagnosi
therapi
liu
et
al
select
rna
aptam
purifi
hbsag
protein
initi
mer
rna
librari
sequenc
aptam
bound
specif
hbsag
hepatoma
cell
line
hbsagdevoid
cell
although
aptam
shown
bind
hbv
surfac
antigen
bind
affin
potenti
crossreact
l
version
surfac
antigen
abil
interfer
particl
assembl
describ
specif
interact
hbv
polymeras
p
protein
rna
stemloop
end
hbv
pregenom
pg
rna
uniqu
characterist
hbv
replic
interact
requir
assembl
replicationcompet
capsid
beyond
hbv
replic
format
complex
necessari
proteinprim
revers
transcript
rna
intermedi
thu
molecul
inhibit
interact
block
viral
replic
pgrna
packag
revers
transcript
level
recent
feng
et
al
use
selex
identifi
potenti
decoy
rna
librari
sought
decoy
mimick
secondari
structur
natur
rna
rna
contain
lower
stem
upper
stem
bulg
apic
loop
screen
librari
design
upper
stem
rna
pool
random
sequenc
lower
stem
bulg
apic
loop
preserv
three
round
select
truncat
p
protein
aptam
display
higher
bind
truncat
p
protein
wildtyp
rna
also
cotransfect
rna
vector
hbv
express
plasmid
reduc
amount
viral
replic
dna
intermedi
aptam
strongli
inhibit
pgrna
packag
dna
synthesi
step
hbv
replic
suggest
act
decoy
compet
natur
pgrna
upon
bind
p
protein
notabl
sign
cytotox
aptamertransfect
cell
sever
acut
respiratori
syndrom
sar
lifethreaten
form
pneumonia
caus
almost
death
caus
agent
sar
sar
coronaviru
scov
envelop
singlestrand
rna
viru
genom
kb
within
week
start
outbreak
scov
genom
structur
determin
encod
two
larg
replic
polyprotein
structur
protein
includ
spike
membran
envelop
e
nucleocapsid
n
protein
four
structur
protein
gener
viru
particl
although
infect
control
measur
surveil
success
contain
spread
scov
human
still
effect
therapeut
regimen
viru
scov
helicas
necessari
viral
replic
prolifer
thu
offer
attract
target
develop
antiscov
aptam
two
studi
independ
isol
potent
nucleic
acid
aptam
dna
rna
protein
aptam
demonstr
subnanomolar
valu
helicas
interestingli
scov
helicas
contain
function
domain
doublestrand
nucleic
acid
unwind
atpas
activ
howev
nucleic
acid
unwind
activ
protein
inhibit
aptam
atpas
activ
affect
suggest
aptam
may
bind
nucleic
acid
bind
site
helicas
block
unwind
activ
intriguingli
phenomenon
observ
hbv
hcv
helicas
inhibit
mediat
aptam
although
dna
rna
aptam
scov
helicas
select
similar
seen
sequenc
recent
newli
discov
coronaviru
name
middl
east
respiratori
syndrom
coronaviru
merscov
identifi
saudi
arabia
produc
clinic
symptom
resembl
sar
merscov
scov
belong
genu
betacoronaviru
howev
genet
distinct
replicas
domain
less
amino
acid
ident
unlik
scov
helicas
aptam
use
treatment
merscov
infect
influenza
consid
preval
infecti
diseas
human
past
centuri
viru
account
three
major
pandem
cumul
kill
ten
million
individu
particular
influenza
also
known
spanish
flu
kill
million
peopl
around
globe
recent
emerg
china
rais
concern
fortun
sustain
persontoperson
spread
virus
confirm
date
three
major
genet
distinct
influenza
virus
type
b
c
influenza
infect
variou
anim
host
high
evolutionari
rate
respons
mani
major
flu
pandem
hand
influenza
b
c
usual
caus
rel
mild
ill
less
concern
gener
influenza
virus
envelop
singlestrand
rna
virus
contain
eight
neg
strand
rna
segment
two
membran
glycoprotein
compon
hemagglutinin
ha
neuraminidas
na
mutat
antigen
drift
reassort
genom
segment
antigen
shift
led
evolut
variou
strain
influenza
strain
classifi
accord
h
number
ha
n
number
na
exampl
viru
design
influenza
viru
subtyp
ha
protein
na
protein
ha
na
protein
serv
prime
target
sever
fdaapprov
small
molecul
vaccin
howev
influenza
highli
adapt
drug
wide
use
strain
resist
treatment
ha
antigen
ubiquit
express
copi
per
viru
surfac
viral
particl
requir
bind
membran
fusion
host
cell
mediat
earli
stage
viral
infect
far
eight
aptam
influenza
virus
develop
therapeut
purpos
aptam
target
ha
tabl
earli
studi
jeon
et
al
evolv
dna
aptam
ha
peptid
posit
conserv
receptor
bind
pocket
among
subtyp
base
hemagglutin
assay
enzymelink
immunosorb
assay
elisa
aptam
found
effici
block
hemagglutin
variou
strain
aport
use
picomolar
rang
moreov
aptam
inhibit
hemagglutinin
capac
viru
also
prevent
viral
bind
entri
cell
importantli
intranas
administr
aptam
influenzainfect
mice
reduc
viru
burden
compar
amount
inhibit
seen
mice
treatment
nabas
drug
current
avail
clinic
similar
studi
gopinath
et
al
devis
novel
select
strategi
use
whole
viru
instead
purifi
protein
select
target
isol
aptam
approach
subtyp
initi
incub
rna
librari
follow
counterselect
anoth
subtyp
aaichi
close
relat
way
aptam
identifi
block
viralcel
interact
bind
ha
target
strain
fail
recogn
influenza
subtyp
although
mani
parallel
aptam
antibodi
technolog
studi
clearli
demonstr
isol
aptam
display
differ
molecular
recognit
mechan
higher
bind
affin
ha
comparison
commerci
avail
antiha
monoclon
antibodi
aptam
potenti
develop
therapeut
agent
could
use
genotyp
reagent
identifi
differ
influenza
subtyp
recent
gopinath
et
al
isol
modifi
aptam
specif
target
ha
protein
virus
one
aptam
optim
display
strong
bind
affin
determin
surfac
plasmon
reson
moreov
aptam
could
distinguish
ha
subtyp
interfer
haglycan
interact
although
influenza
b
differ
biolog
mechan
well
evolutionari
characterist
genet
lineag
larg
similar
symptom
caus
infect
therefor
aptam
specif
recogn
influenza
b
viru
would
use
therapeut
diagnost
perspect
similarli
rna
aptam
specif
influenza
b
isol
influenza
viru
isol
aptam
bound
specif
ha
influenza
b
viru
influenza
viru
interestingli
ha
recognit
aptam
requir
magnesium
ion
order
inhibit
hamedi
membran
fusion
rabi
viral
diseas
caus
nerv
damag
death
mani
mammal
caus
agent
rabi
rabi
viru
rabv
transmit
speci
often
saliva
transfer
bite
rabid
anim
current
effect
treatment
rabi
symptom
develop
death
occur
within
week
although
postexposur
rabi
treatment
avail
treat
rabvinfect
patent
viru
invad
central
nervou
system
viru
still
caus
death
annual
worldwid
liang
et
al
twice
use
cellselex
approach
attempt
isol
dna
aptam
rabv
first
studi
aptam
isol
iter
round
select
librari
first
incub
rabi
viru
infect
babi
hamster
kidney
bhk
cell
follow
counterselect
uninfect
cell
process
identifi
five
aptam
inhibit
replic
rabv
although
aptam
bound
tightli
viru
inhibitori
capac
limit
crossreact
rabi
strain
led
group
use
cellselex
approach
select
new
batch
aptam
second
attempt
dna
aptam
isol
aptam
inhibit
significantli
replic
rabv
relat
virus
aptam
modifi
polyethylen
glycol
peg
vivo
test
show
aptam
effect
protect
infect
mice
enabl
surviv
rate
mice
treat
aptam
day
prior
challeng
rabv
howev
almost
mice
die
challeng
rabv
prior
treatment
aptam
rabv
replic
rapidli
produc
larg
amount
infecti
particl
enter
brain
make
aptam
ineffect
sever
group
select
nucleic
acid
protein
demonstr
similar
result
role
cell
wellcharacter
protein
interact
cell
cycl
control
protein
prb
inhibit
bind
transcript
factor
lead
unrestrict
bypass
check
point
cell
cycl
addit
shown
interact
wide
rang
cellular
factor
includ
tata
bind
protein
nicol
et
al
identifi
function
rna
aptam
disrupt
interact
prb
protein
mutagenesi
assay
show
aptam
bound
ntermin
residu
known
involv
interact
prb
transfect
hpvinfect
cancer
cell
aptam
result
loss
elev
prb
level
lead
cell
apoptosi
herp
simplex
viru
hsv
often
infect
primari
epitheli
tissu
invad
nervou
system
becom
latent
two
form
hsv
share
genom
ident
ubiquit
highli
contagi
effect
treatment
erad
viru
total
bodi
akin
antivir
drug
block
viral
entri
antihsv
aptam
evolv
glycoprotein
gd
gd
protein
essenti
viral
surfac
protein
requir
bind
host
cell
receptor
viral
entri
fusion
aptam
select
aptam
evolv
specif
bind
gd
protein
use
proteinbas
selex
although
gd
protein
highli
homolog
sequenc
ident
aptam
discrimin
two
chemic
modif
aptam
fluoro
increas
stabil
rna
nucleas
degrad
greatli
affect
bind
capac
furthermor
aptam
effect
inhibit
entri
cell
block
interact
gd
protein
target
cell
receptor
similarli
aptam
select
gd
protein
counterselect
igg
remov
nonspecif
binder
panel
aptam
shown
neutral
infect
depend
two
entri
receptor
nectin
hvem
one
effect
aptam
inhibit
infect
vero
cell
nm
inhibit
requir
accca
motif
bind
function
given
import
infect
enhanc
risk
transmiss
aptam
propos
incorpor
microbicid
reduc
spread
well
sinc
first
public
selex
two
decad
ago
develop
aptam
technolog
advanc
rapidli
laboratori
earli
midstag
clinic
develop
aptam
also
describ
chemic
version
antibodi
inhibit
target
specif
strong
interact
superior
biolog
small
molecul
therapeut
yet
avoid
toxic
immunogen
concern
tradit
agent
deriv
nucleic
acid
composit
latest
advanc
selex
technolog
chemic
conjug
method
given
aptam
remark
potenti
use
smart
bomb
deliv
secondari
therapeut
cargo
diseas
cell
sever
exampl
eg
aptamersirna
chimera
aptamerribozym
chimera
aptameraptam
chimera
discuss
review
demonstr
complementari
versatil
approach
combin
strength
aptam
nucleic
acidbas
therapeut
offer
polyval
platform
treat
variou
diseas
chimera
offer
huge
potenti
provid
enhanc
therapeut
potenc
reduc
cellular
toxic
drug
howev
despit
substanti
advanc
describ
aptam
yet
reach
clinic
develop
pipelin
antivir
therapi
aptam
whose
target
express
intracellularli
unlik
use
clinic
aptam
hydrophil
therefor
pass
epithelia
hydrophob
plasma
membran
consequ
aptam
target
extracellular
viral
protein
capsid
protein
virion
influenza
ha
like
suitabl
clinic
therapeut
develop
addit
aptam
chimera
approach
anoth
potenti
approach
solv
problem
would
use
viral
vector
transient
express
aptam
intracellularli
exampl
bai
et
al
design
lentivir
vector
encod
antihiv
ribozym
togeth
antitat
aptam
construct
test
hivinfect
human
mice
abl
inhibit
viru
replic
howev
conclus
whether
aptam
contribut
inhibitori
effect
furthermor
typic
nucleic
acid
entiti
nake
nucleic
acid
aptam
rel
small
sensit
nucleas
degrad
averag
diamet
usual
less
nm
therefor
rapidli
remov
blood
renal
clearanc
thu
intrins
physicochem
featur
aptam
pose
seriou
challeng
transport
infect
organ
cell
liver
central
nervou
system
follow
system
administr
blood
stream
typic
respiratori
virus
influenza
virus
scov
wellsuit
target
aptam
therapeut
upper
airway
lung
rel
easi
access
target
organ
therefor
may
possibl
block
respiratori
viru
infect
use
aptamercontain
aerosol
similarli
sexual
transmit
virus
hpv
might
target
intravagin
applic
microbicid
cream
contain
neutral
aptam
although
topic
microbicid
might
protect
women
virus
intercours
femal
genit
tract
abund
variou
nucleas
degrad
nucleic
acid
aptam
even
f
modifi
one
minut
one
way
improv
aptam
stabil
chemic
introduc
modif
purin
nucleotid
phosphorothio
linkag
moreov
zinc
ion
incorpor
formul
nucleas
sensit
inhibit
zinc
ion
recent
wheeler
et
al
develop
topic
microbicid
contain
chemic
modifi
aptamersirna
chimera
target
hiv
coreceptor
gag
vif
protect
sexual
transmiss
chimera
stabil
formul
hydroxyethyl
cellulos
gel
fdaapprov
polym
alreadi
use
clinic
trial
achiev
durabl
gene
knockdown
inhibit
transmiss
mice
use
aptam
therapeut
agent
still
earli
stage
develop
howev
innov
flexibl
selex
methodolog
allow
aptam
technolog
becom
major
player
altern
approach
battl
viral
diseas
